Sickle Cell Has New Technology. Why Has Access Taken So Long?
Around 17,000 people in England live with sickle cell disease, an inherited blood disorder that can cause episodes of severe pain, organ damage and potentially life-threatening complications. Around 250 new cases are diagnosed each year, and the condition is particularly common among people of Black African and Caribbean heritage, as well as people with Middle Eastern and South Asian backgrounds.
In June 2025, the government and NHS England announced a further £9 million investment to expand access to automated red blood cell exchange technology for people living with the condition.
The investment is undoubtedly welcome. However, it also raises a more uncomfortable question about healthcare innovation and inequality. If technology can improve patients’ lives while reducing costs to the NHS, why does access to it remain uneven?
What Does the Technology Actually Do?
Sickle cell disease affects haemoglobin, the protein in red blood cells responsible for carrying oxygen around the body. The condition causes some red blood cells to become rigid and develop their characteristic sickle shape. These cells can obstruct blood vessels, restrict oxygen supply and cause severe episodes known as sickle cell crises.
Blood transfusion is one of the treatments used to manage the condition.
Spectra Optia provides a more sophisticated approach known as automated red blood cell exchange. Instead of simply adding donor blood to the patient’s existing blood, the machine removes sickled red blood cells and replaces them with healthy donor cells.
For eligible patients who require regular exchanges, this can provide important advantages. The treatment can remain effective for longer than simple transfusions and can reduce complications including iron overload, which can occur when repeated transfusions cause excess iron to accumulate in the body.
There is also an economic argument. NHS England estimates that replacing simple top-up and manual exchange transfusions with this technology could save almost £19,000 per patient each year. Across the health service, the government estimates that greater use of the technology has the potential to save as much as £12.9 million annually through reduced hospital stays and lower requirements for other treatments.
The Human Impact Is More Important Than the Machine
The strongest argument for the technology is not found on a spreadsheet.
Robert Ojeer, a 35-year-old father from west London, has lived with sickle cell disease throughout his life. Before joining a regular automated exchange programme, he received exchanges primarily during emergencies involving more complicated sickle cell crises.
He now receives automated red cell exchanges every four weeks at Hammersmith Hospital.
Ojeer told the government that regular access to the treatment had improved his quality of life, allowing him to play a greater role in the lives of his two children, continue working and experience a greater sense of normality.
His experience also exposes the importance of geography.
Ojeer lives around 20 minutes from a hospital with the necessary equipment. Other people with the same condition may not.
A medical technology cannot reduce healthcare inequality if the people who would benefit from it cannot reasonably access it.
The Access Problem
More than 20 NHS trusts were supported to provide Spectra Optia treatment for sickle cell patients when the £9 million expansion was announced.
This was not the first attempt to improve access. NHS England had already announced £1.5 million in 2024 for 25 automated red blood cell exchange devices distributed across 22 NHS trusts.
The latest investment therefore represents another stage in expanding the service rather than the sudden introduction of a new technology.
The £9 million programme is intended to increase the number of specialist treatment centres, improve nationwide availability, expand out-of-hours provision and develop the specialist workforce required to operate the technology.
That last point is important because buying a machine does not automatically create a healthcare service.
Hospitals need trained staff, blood supplies, appropriate facilities, commissioning arrangements and sufficient capacity to provide regular treatment. Technology adoption in healthcare is therefore partly an infrastructure and workforce problem.
Nevertheless, the uneven availability of treatment deserves scrutiny when the condition itself already sits within a wider pattern of health inequality.
Sickle Cell and Healthcare Inequality
Sickle cell disease disproportionately affects Black African and Black Caribbean communities in England.
NHS England has also acknowledged that many patients affected by the condition live in some of the country’s most socio-economically deprived areas and experience higher risks of hospital readmission and in-hospital mortality.
This makes access more than a question of purchasing medical equipment.
It becomes a question of health equity.
If a disease disproportionately affects communities already experiencing poorer health outcomes, delays or geographical inequalities in accessing specialist treatment can compound disadvantages that already exist.
The important question is therefore not simply whether the NHS possesses innovative technology. It is whether patients can benefit from that technology regardless of where they live.
What Is Changing?
The latest investment is designed to address several of those barriers.
| Area | What Is Changing | Why It Matters |
|---|---|---|
| Automated red cell exchange | Spectra Optia machines are being made more widely available. | More eligible patients could access regular automated exchanges rather than relying on less advanced approaches. |
| Specialist centres | Funding is intended to expand treatment capacity. | Geography should become less of a barrier to accessing specialist care. |
| Out-of-hours treatment | Services are being expanded beyond conventional operating hours. | Sickle cell complications do not occur according to hospital office hours. |
| Specialist workforce | Investment includes developing staff capable of delivering advanced apheresis treatment. | Equipment is ineffective without trained people and clinical infrastructure around it. |
| Longer-term care | Greater capacity should support more regular treatment rather than relying primarily on emergency intervention. | Preventative and planned care can improve quality of life and reduce hospital pressure. |
The distinction between emergency medicine and planned treatment is particularly important.
A healthcare system should not simply become better at treating people when they reach crisis point. Where possible, technology should help prevent those crises from happening in the first place.
Then Came Gene Editing
The technological landscape surrounding sickle cell disease is changing in another extraordinary way.
In early 2025, NICE recommended exagamglogene autotemcel, also known as exa-cel or Casgevy, under a managed access arrangement for some people aged 12 and over with severe sickle cell disease.
The treatment uses CRISPR gene-editing technology. A patient’s own blood-producing stem cells are collected and genetically edited so that, once returned to the body, they can produce red blood cells that resist sickling.
For eligible patients, it offers the possibility of a functional cure.
However, this is not a treatment for everybody with sickle cell disease. NICE’s recommendation applies to specific patients with recurrent severe crises for whom a stem-cell transplant is considered appropriate but who do not have a suitable matched related donor.
That distinction matters because spectacular breakthroughs can sometimes distract from the less glamorous challenge of ensuring that existing treatments reach everybody who needs them.
A million-pound gene therapy can transform an individual life. So can making sure a patient can access an established blood-exchange service close to home.
Innovation matters at both ends of the spectrum.
The Priority Problem
The £9 million investment should therefore be welcomed. More machines, greater treatment capacity, expanded out-of-hours services and investment in specialist staff could make a meaningful difference to people living with sickle cell disease.
The more difficult question is what the history of access tells us about how healthcare systems prioritise innovation.
Healthcare inequality does not always appear as somebody being explicitly denied treatment. Sometimes it appears as geography. Sometimes it appears as workforce shortages. Sometimes it appears as technology being available in one hospital but not another. Sometimes it appears as years spent waiting for infrastructure around an existing innovation to catch up.
That is why sickle cell provides an important case study.
The technology exists. NHS England says it improves the patient experience. The government says it can reduce complications. The NHS estimates that it can save almost £19,000 per patient each year.
The challenge is making those benefits routinely accessible to the people who need them.
The Bigger Picture
Healthcare innovation is often discussed through the language of discovery. We celebrate the new drug, the new machine and the scientific breakthrough.
But invention is only the first half of innovation.
The second half is diffusion: getting an effective technology out of specialist centres and into the healthcare system at sufficient scale for patients to benefit.
For conditions such as sickle cell disease, that distinction has an additional dimension because the burden of disease falls disproportionately on communities that have historically experienced health inequalities.
The measure of progress therefore cannot simply be whether Britain possesses world-leading medical technology.
It must also be who gets access to it, where they get access to it and how long they have to wait.
When a life-changing technology exists but access to it remains uneven, the innovation problem is no longer simply what we can invent. It is what we choose to prioritise, fund and make available to everyone who needs it.